186 studies found for:    "Essential thrombocythemia"
Show Display Options
Rank Status Study
21 Completed Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide;   Drug: Hydroxyurea
22 Active, not recruiting Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Intervention: Drug: SPD422 (anagrelide hydrochloride)
23 Recruiting Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide retard;   Drug: Placebo
24 Completed
Has Results
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythaemia
Intervention: Drug: anagrelide hydrochloride
25 Completed Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib
26 Active, not recruiting An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Fibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
27 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
28 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
29 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
30 Completed Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Conditions: Polycythemia Vera;   Essential Thrombocytosis
Intervention: Drug: lestaurtinib
31 Completed Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Post-polycythemia Vera Related Myelofibrosis;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
32 Recruiting Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Drug: Momelotinib;   Drug: Ruxolitinib;   Drug: Placebo to match momelotinib;   Drug: Placebo to match ruxolitinib
33 Recruiting A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Biological: PRM-151;   Drug: Ruxolitinib
34 Active, not recruiting LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Related Myelofibrosis;   Post-Essential Thrombocythemia Related Myelofibrosis
Intervention: Drug: LBH589
35 Active, not recruiting Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Conditions: Primary Myelofibrosis (MF);   Post-Polycythemia Vera (PV) MF;   Post-Essential Thrombocythemia (ET) MF
Intervention: Drug: Ruxolitinib
36 Active, not recruiting Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Conditions: Primary Myelofibrosis (PMF);   Post-Polycythaemia Vera;   Essential Thrombocythaemia Myelofibrosis
Intervention: Drug: AZD1480
37 Active, not recruiting CEP-701 (Lestaurtinib) in Myelofibrosis
Conditions: Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: CEP-701 (Lestaurtinib)
38 Recruiting Research Tissue Bank
Conditions: Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:
39 Completed A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Conditions: Myelofibrosis;   Myeloproliferative Disorders;   Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: SB1518
40 Recruiting Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Conditions: Myeloproliferative Disease;   Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years